SGLT-2 inhibitors stave off type 2 diabetes in HF, studies show
The agents may lower the risk of new-onset diabetes in these patients by up to a third, researchers say.
New analyses of trial data suggest SGLT-2 inhibitors reduce incident diabetes in patients with cardiovascular or kidney disease, a team of international researchers says.
Dapagliflozin was associated with a 33% lower risk of new-onset diabetes in one study, suggesting it was a candidate for upstream prevention among patients with heart failure (HF), the Harvard University-led team reported.
